In Segment A, members will acquire distinct doses and schedules of oral ABBV-744 tablet to detect Risk-free dosing program. Extra members will be enrolled at the recognized monotherapy dosign routine. In Section B, members will acquire oral ruxolitinib and ABBV-744 will likely be supplied as "add-on" therapy. In Segment C, https://clinical-effectiveness-of42619.iyublog.com/31276486/the-basic-principles-of-abbv-744-in-acute-myeloid-leukemia-aml